Bioburden Testing Market Size To Reach $3.22 Billion By 2030

Bioburden Testing Market Growth & Trends

The global bioburden testing market size is estimated to reach USD 3.22 billion by 2030, registering to grow at a CAGR of 14.5% from 2025 to 2030 according to a new report by Grand View Research, Inc. The market is expected to showcase upward trend in the forthcoming years owing to growing concerns about product safety. This has led to various government initiatives to promote microbiological safety testing tools.

A number of publications released by organizations to promote awareness regarding microbiological safety testing is broadening the future growth prospects of bioburden testing. For instance, the U.S. Department of Health and Human Services and Centers for Disease Control published Biosafety in Microbiological and Biomedical Laboratories (BMBL), which includes information pertaining to laboratory biosecurity and risk assessment, decontamination and sterilization, and biological toxins and biosafety levels in laboratories.

Growth of pharmaceutical, biotechnology, medical device, and food and beverage industries have contributed to the high growth of the bioburden testing market. In addition, increase in R&D investments by prominent companies is expected to encourage end users to adopt highly efficient bioburden testing tools to counter possible losses due to microbial contamination. Moreover, requirement for basic drug safety data requirements for preclinical studies is expected to fuel the demand for bioburden testing tools.

 Request a free sample copy or view report summary: Bioburden Testing Market Report

Bioburden Testing Market Report Highlights

• Consumables dominated the bioburden testing market, accounting for the highest revenue share of 66.4% in 2024. The segment is further divided into culture media, reagents, and kits. 

• Aerobic count testing led the bioburden testing market, accounting for the largest revenue share of 36.6% in 2024. 

• The raw material testing sector dominated the bioburden testing market, with the largest revenue share of 30.4% in 2024.

• Pharmaceutical and biotechnology companies dominated the bioburden testing market with the largest revenue share in 2024.  

Bioburden Testing Market Segmentation

Grand View Research has segmented the global bioburden testing market based on product, test type, application, end-use, and region:

Bioburden Testing Product Outlook (Revenue, USD Million; 2018 - 2030)

• Consumables

  • Culture Media

  • Reagents and Kits

• Instruments

  • Automated Microbial Identification Systems

  • PCR Instruments

Bioburden Testing Test Type Outlook (Revenue, USD Million; 2018 - 2030)

• Aerobic Count Testing

• Anaerobic Count Testing

• Fungi/Mold Count Testing

• Spore Count Testing

Bioburden Testing Application Outlook (Revenue, USD Million; 2018 - 2030)

• Raw Material Testing

• Medical Device Testing

• In-Process Material Testing

• Sterilization Validation Testing

• Equipment Cleaning Validation

Bioburden Testing End-use Outlook (Revenue, USD Million; 2018 - 2030)

• Pharmaceutical & Biotechnology Companies

• Medical Device Manufacturers

• Contract Manufacturing Organizations

• Manufacturers of Food & Beverage and Agricultural Products

• Microbial Testing Laboratories

Bioburden Testing Regional Outlook (Revenue, USD Million; 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Bioburden Testing Market

• Charles River Laboratories

• Merck KGaA

• SGS SA

• WuXi AppTec

• BD

• North American Science Associates Inc.

• Nelson Laboratories, LLC

• Thermo Fisher Scientific Inc.

• BIOMÉRIEUX

• Pacific Biolabs